Exosome Diagnostics Inc (Exosome Diagnostics) is a provider of diagnostic solutions. The company develops, designs, manufactures and markets biofluid-based molecular diagnostic tests and products for use in personalized medicine. Exosome Diagnostics' services comprises of miRNA profiling, mRNA profiling, mutation detection, ribonucleic acid (RNA) sequencing (including full RNA seq) and custom assay development services. The company also offers disease detection, diagnosis, treatment and monitoring. Exosome Diagnostics pharma services includes Exosome Enrichment and Exosome Depletion. Its technology is used in the treatment of brain cancer, prostate cancer, and Alzheimer's disease. Exosome Diagnostics is headquartered in Waltham, Massachusetts, the United States.
This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Exosome Diagnostics Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Exosome Diagnostics Inc Company Overview
- Exosome Diagnostics Inc Company Snapshot
- Exosome Diagnostics Inc Pipeline Products and Ongoing Clinical Trials Overview
- Exosome Diagnostics Inc - Pipeline Analysis Overview
- Exosome Diagnostics Inc - Key Facts
- Exosome Diagnostics Inc - Major Products and Services
- Exosome Diagnostics Inc Pipeline Products by Development Stage
- Exosome Diagnostics Inc Pipeline Products Overview
- Biofluid Nucleic Acid Kit - Alzheimer's Disease
- Biofluid Nucleic Acid Kit - Alzheimer's Disease Product Overview
- Biofluid Nucleic Acid Kit - Cardiovascular Disease
- Biofluid Nucleic Acid Kit - Cardiovascular Disease Product Overview
- Biofluid Nucleic Acid Kit - Chronic Kidney Disease
- Biofluid Nucleic Acid Kit - Chronic Kidney Disease Product Overview
- Biofluid Nucleic Acid Kit - Parkinson's Disease
- Biofluid Nucleic Acid Kit - Parkinson's Disease Product Overview
- Biofluid-Based Molecular Diagnostic Test - Brain Cancer
- Biofluid-Based Molecular Diagnostic Test - Brain Cancer Product Overview
- BIONIC Liquid Biopsy - Bladder Cancer
- BIONIC Liquid Biopsy - Bladder Cancer Product Overview
- Diagnostic Assay - Arv7
- Diagnostic Assay - Arv7 Product Overview
- Diagnostic Assay - BRAF
- Diagnostic Assay - BRAF Product Overview
- Diagnostic Assay - Breast Cancer Signature
- Diagnostic Assay - Breast Cancer Signature Product Overview
- Diagnostic Assay - IDH1
- Diagnostic Assay - IDH1 Product Overview
- Diagnostic Test - Parkinson's Disease
- Diagnostic Test - Parkinson's Disease Product Overview
- EGFR 29 Mutation Panel
- EGFR 29 Mutation Panel Product Overview
- ExoTRU Kidney Transplant Rejection Test
- ExoTRU Kidney Transplant Rejection Test Product Overview
- Midi Lung Cancer Panel
- Midi Lung Cancer Panel Product Overview
- Next-Generation Solid Tumor Mutation Panel
- Next-Generation Solid Tumor Mutation Panel Product Overview
- Sjogren Syndrome Assay
- Sjogren Syndrome Assay Product Overview
- Exosome Diagnostics Inc - Key Competitors
- Exosome Diagnostics Inc - Key Employees
- Exosome Diagnostics Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Exosome Diagnostics Inc, Recent Developments
- Oct 10, 2019: Medicare issues final local coverage decision for bio-Techne's ExoDx Prostate(IntelliScore) Test
- Jun 17, 2019: FDA grants breakthrough device designation to Bio-Techne's ExoDx Prostate IntelliScore (EPI) Test
- Jun 13, 2019: Bio-Techne receives approval to offer The ExoDx Prostate Intelliscore (EPI) test in New York State
- Sep 18, 2018: Bio-Techne announces publication of data demonstrating additional clinical validation of its EPI Test in European Urology Journal
- Jun 13, 2018: Exosome Diagnostics Receives ISO 13485:2016 Certification
- May 22, 2018: Exosome Diagnostics Announces Bladder Cancer Surveillance Panel
- May 22, 2018: Exosome Diagnostics Announces Bladder Cancer Surveillance Panel
- May 17, 2018: Exosome Diagnostics’ Second Prospective Validation Study of EPI to be Highlighted at American Urological Association (AUA) Annual Meeting Press Briefing in San Francisco, CA
- May 15, 2018: Exosome Diagnostics Presents Breakthrough Data Highlighting Tumor Derived RNA in Biofluids at the International Society for Extracellular Vesicles in Spain
- May 09, 2018: Exosome Diagnostics Continues to Expand Coverage Reach for its EPI Test
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Exosome Diagnostics Inc Pipeline Products and Ongoing Clinical Trials Overview
- Exosome Diagnostics Inc Pipeline Products by Equipment Type
- Exosome Diagnostics Inc Pipeline Products by Indication
- Exosome Diagnostics Inc, Key Facts
- Exosome Diagnostics Inc, Major Products and Services
- Exosome Diagnostics Inc Number of Pipeline Products by Development Stage
- Exosome Diagnostics Inc Pipeline Products Summary by Development Stage
- Biofluid Nucleic Acid Kit - Alzheimer's Disease - Product Status
- Biofluid Nucleic Acid Kit - Alzheimer's Disease - Product Description
- Biofluid Nucleic Acid Kit - Cardiovascular Disease - Product Status
- Biofluid Nucleic Acid Kit - Cardiovascular Disease - Product Description
- Biofluid Nucleic Acid Kit - Chronic Kidney Disease - Product Status
- Biofluid Nucleic Acid Kit - Chronic Kidney Disease - Product Description
- Biofluid Nucleic Acid Kit - Parkinson's Disease - Product Status
- Biofluid Nucleic Acid Kit - Parkinson's Disease - Product Description
- Biofluid-Based Molecular Diagnostic Test - Brain Cancer - Product Status
- Biofluid-Based Molecular Diagnostic Test - Brain Cancer - Product Description
- BIONIC Liquid Biopsy - Bladder Cancer - Product Status
- BIONIC Liquid Biopsy - Bladder Cancer - Product Description
- Diagnostic Assay - Arv7 - Product Status
- Diagnostic Assay - Arv7 - Product Description
- Diagnostic Assay - BRAF - Product Status
- Diagnostic Assay - BRAF - Product Description
- Diagnostic Assay - Breast Cancer Signature - Product Status
- Diagnostic Assay - Breast Cancer Signature - Product Description
- Diagnostic Assay - IDH1 - Product Status
- Diagnostic Assay - IDH1 - Product Description
- Diagnostic Test - Parkinson's Disease - Product Status
- Diagnostic Test - Parkinson's Disease - Product Description
- EGFR 29 Mutation Panel - Product Status
- EGFR 29 Mutation Panel - Product Description
- ExoTRU Kidney Transplant Rejection Test - Product Status
- ExoTRU Kidney Transplant Rejection Test - Product Description
- Midi Lung Cancer Panel - Product Status
- Midi Lung Cancer Panel - Product Description
- Next-Generation Solid Tumor Mutation Panel - Product Status
- Next-Generation Solid Tumor Mutation Panel - Product Description
- Sjogren Syndrome Assay - Product Status
- Sjogren Syndrome Assay - Product Description
- Exosome Diagnostics Inc, Key Employees
- Exosome Diagnostics Inc, Subsidiaries
- Glossary
- Exosome Diagnostics Inc Pipeline Products by Equipment Type
- Exosome Diagnostics Inc Pipeline Products by Development Stage
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Lifelines Neurodiagnostic Systems Inc
- Freenome Inc
- DEYMED Diagnostic
- Image Diagnostics Inc
- Biocell Laboratories Inc
- ActivX Biosciences Inc
